On Friday, when the panel will focus on J&J, the NIH will present findings from its mix-and-match booster study, according to the draft agenda of the meeting.

That data is expected to show a significantly stronger neutralizing antibody response — which is a form of immune protection — to an mRNA booster than to a second dose of J&J.

But J&J hasn’t asked the FDA to authorize mixing and matching its vaccine with another one, which could make the process messy. It’s unclear how a mix-and-match authorization process would play out.

But, but, but: There are limitations to the NIH data. Neutralizing antibodies are only one form of immune protection, and it’s unclear how long the response will last.